Trial · NCT02228460
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 1 / Week 26 Score: 1 | 4 | Participants | |
Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 1 / Week 26 Score: 2 | 1 | Participants | |
Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 2 / Week 26 Score: 1 | 3 | Participants | |
Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 2 / Week 26 Score: 2 | 1 | Participants | |
| Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium | GZ/SAR402671 | -0.22 | 95% Confidence Interval -0.73 to 0.29 | score on a scale | |
| Change From Baseline in Plasma GL-3 Concentration at Week 26 | GZ/SAR402671 | -3.62 | Standard Deviation 1.07 | mcg/mL | |
| Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26 | GZ/SAR402671 | -30.99 | Standard Deviation 22.83 | ng/mL | |
| Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26 | GZ/SAR402671 | -3.26 | Standard Deviation 1.43 | mcg/mL | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 1 / Week 26 Score: 1 | 1 | Participants | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 2 / Week 26 Score: 1 | 2 | Participants | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 2 / Week 26 Score: 2 | 6 | Participants | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 1.5 / Week 26 Score: 1.5 | 2 | Participants | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 2 / Week 26 Score: 2 | 7 | Participants | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 1 / Week 26 Score: 2 | 1 | Participants | |
| Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26 | GZ/SAR402671 | Baseline Score: 2 / Week 26 Score: 2 | 8 | Participants | |
| Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26 | GZ/SAR402671 | -0.25 | Standard Deviation 0.19 | mg/mmol Cr | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | GZ/SAR402671 | 9 | Participants | ||
| Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671 | GZ/SAR402671 | Day 1 | 24.7 | Standard Deviation 5.89 | ng/mL |
| Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671 | GZ/SAR402671 | Day 182 | 192.0 | Standard Deviation 96.4 | ng/mL |
| PK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671 | GZ/SAR402671 | Day 14 | 152.0 | Standard Deviation 68.9 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02228460/results